01557nas a2200289   4500000000100000008004100001260001300042653001200055653003100067653003000098653001100128653002100139653002300160653001200183653000900195653002400204653002500228653001400253653001300267100001300280700001200293245013800305300001000443490000700453520079300460022001401253       2003                            d  c2003 Mar10aAnimals10aDrug Resistance, Bacterial10aDrug Therapy, Combination10aFemale10aFluoroquinolones10aLeprostatic Agents10aleprosy10aMice10aMice, Inbred BALB C10aMycobacterium leprae10aOfloxacin10aRifampin1 aDhople A1 aNamba K00aIn vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.  a251-50 v213 a<p>The antimicrobial effects of sitafloxacin (DU-6859a) against Mycobacterium leprae, either singly or in combination with either rifampicin, rifabutin or KRM-1648, were studied using a mouse footpad assay technique and the results were compared with those obtained with ofloxacin. When used singly, the minimum concentrations of sitafloxacin and ofloxacin needed to inhibit completely the growth of M. leprae were 25 and 100 mg per kg body weight per day, respectively, and the effects were bactericidal. Both sitafloxacin and ofloxacin exhibited excellent synergistic effects when combined with either rifabutin or KRM-1648, but not with rifampicin. Thus, incorporation of sitafloxacin and rifabutin (or KRM-1648) in the multidrug regimen for treating leprosy patients is suggested.</p>  a0924-8579